As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?
This article was originally published in Start Up
Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.
You may also be interested in...
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.